Reversible Portal Vein Embolization Before Major Hepatectomy

Assistance Publique - Hôpitaux de Paris33 enrolled

Overview

The aim of this study is to prospectively evaluate the tolerance and efficiency of a new technique of preoperative selective portal vein embolization (PVE) in patients requiring major hepatic resection.

Portal vein embolization (PVE) is used before major hepatectomy to induce hypertrophy of the future liver remnant (FLR). A non-reversible absorbable material is generally used for embolization, as it provides effective, permanent vascular occlusion. Our team has developed a minimally invasive technique of reversible PVE using gelfoam powder. The aim of this study is to assess the tolerance and efficiency of preoperative reversible selective PVE in patients requiring major hepatic resection. We hypothesize that preoperative reversible PVE allows to similarly increase FLR volume in comparison with classical non-reversible PVE in patients requiring major liver resection with limited FLR. The hypertrophy ratio after classical non-reversible PVE is evaluated in literature as 13%. We estimated the hypertrophy ratio after reversible PVE as 9% in a previous retrospective study. The aim of this pilot study is to prospectively evaluate the hypertrophy ratio after reversible PVE. Primary End Point: Hypertrophy ratio of FLR volume / total liver volume between the baseline and after PVE, assessed by computed tomography scan volumetry 4-6 weeks after PVE.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Liver Regeneration Reversible Portal Vein Embolization

Interventions

Selective reversible portal vein embolizationPROCEDURE

Percutaneous access to the portal vein is achieved under general anesthesia with ultrasound or fluoroscopic control. After assessment of portal venous anatomy, embolization of selected portal vein segments is performed using the powdered form of an absorbable gelatin sponge.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: Patient aged between 18 and 80 years * Patient requiring major liver resection (at least 3 segments) * PVE indication decided in a multidisciplinary meeting * Patients who are able to understand and follow instructions and who are able to participate in the study for the entire period * Patients must have given their written informed consent to participate in the study after having received adequate previous information and prior to any study-specific procedures * Patient affiliated to the French National Social Security System Exclusion Criteria: * American Score of Anesthesiologist (ASA) \> 3 * Extensive Portal vein or hepatic vein thrombosis * Patient not covered by social security service * Patient under guardianship * Patients with a medical disorder, condition, or history of such that would impair the patient's ability to participate or complete this study in the opinion of the investigator. * Patients who have already had anaphylactic or anaphylactoid reactions during the injection of iodinated contrast medium (edema of Quincke…) * Patients with an allergy to pork products During the hospitalization and before the PVE * Severe renal insufficiency (glomerular filtration rate ≤ 30mL/min eg calculated based on the Cockcroft formula). * Pregnant women, or breast feeding women, or women with childbearing potential not using a combination of condoms and a safe and highly effective contraception method during the participation to the research (hormonal contraception with implants or oral contraceptives, or intrauterine devices).

Locations (1)

Antoine Béclère

Clamart, France

Outcomes

Primary Outcomes

Hypertrophy ratio of FLR volume / total liver volume between the baseline and after the PVE

Ratio is evaluated by computed tomography scan volumetry 4-6 weeks after portal vein embolization.Volumes will be assessed by one independent blind observer, from anonymized CT scan series. Total, non-embolized (FLR) volume and embolized liver volume (ELV) will be measured. The following formulas will be used to calculate percentage of FLR volume: * FLR volume prePVE = (FLR prePVE volume / (total liver prePVE volume - tumor volume prePVE)) x 100 * FLR volume postPVE = (FLR postPVE volume / (total liver postPVE volume - tumor volume postPVE)) x 100 The following formulas will be used to calculate hypertrophy ratio: %FLR volume postPVE - %FLR volume prePVE

Time frame: 4-6 weeks after portal vein embolization

Secondary Outcomes

Technical feasibility: Percentage of completed PVE

Percutaneous access to the portal vein is achieved under general anesthesia with ultrasound or fluoroscopic control. Venous cartography of the liver is achieved with fluoroscopic control. PVE technique remains unchanged but a mixture of absorbable embolization agent is injected. Adverse events will be questioned and documented in the electronic Case Report Form.

Time frame: During the procedure of portal vein embolization

Technical feasibility: Percentage of partially completed PVE

Time frame: During the procedure of portal vein embolization

Technical feasibility: Percentage of not performed PVE

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.